ACADIA Pharmaceuticals Inc (ACAD.OQ)
17 May 2013
|Market Cap (Mil.):||$1,151.88|
|Shares Outstanding (Mil.):||86.80|
- Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, and that it would not need to conduct an additional trial as planned earlier.
NEW YORK, March 21 - ACADIA Pharmaceuticals Inc : * Pharma up 6.5 percent to $7.08 in premarket after phase III pimavanserin study data
* Achieves antipsychotic effect without loss of motor function
Earnings vs. Estimates
Analyst Research Reports
Provider: Wright Reports
Provider: Pechala's Reports
ACADIA Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ Quantitative Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.